A Phase Ia/Ib Trial of Revumenib Combined With Cytarabine, Daunorubicin, and Gemtuzumab Ozogamicin (GO) in Frontline and Relapsed /Refractory Pediatric Acute Leukemia Patients

NCT07052994 · clinicaltrials.gov ↗

PHASE1

Phase

NOT_YET_RECRUITING

Status

32

Enrollment

OTHER

Sponsor class

Conditions

Pediatric Acute Leukemia

Interventions

DRUG: Revumenib
DRUG: Cytrabine
DRUG: Daunorubicin

Sponsor

M.D. Anderson Cancer Center